| 23.04 -0.25 (-1.07%) | 05-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.06 | 1-year : | 32.2 |
| Resists | First : | 24.88 | Second : | 27.56 |
| Pivot price | 23.89 |
|||
| Supports | First : | 20.53 | Second : | 17.08 |
| MAs | MA(5) : | 23.88 |
MA(20) : | 24.19 |
| MA(100) : | 27.29 |
MA(250) : | 19.95  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 39.1 |
D(3) : | 45.5 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 37.77 | Low : | 9.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TCMD ] has closed above bottom band by 30.5%. Bollinger Bands are 16.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.68 - 23.91 | 23.91 - 24.04 |
| Low: | 22.49 - 22.79 | 22.79 - 22.97 |
| Close: | 22.7 - 23.18 | 23.18 - 23.47 |
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Wed, 13 May 2026
Tactile Systems CFO sells $113,403 in TCMD common stock - Investing.com
Wed, 13 May 2026
Tactile Systems (TCMD) CFO sells 4,631 shares to cover tax on units - Stock Titan
Tue, 12 May 2026
Tactile Medical projects $360M-$368M 2026 revenue as Medicare prior authorization process matures - MSN
Mon, 11 May 2026
Shareholders Will Be Pleased With The Quality of Tactile Systems Technology's (NASDAQ:TCMD) Earnings - Yahoo Finance
Sat, 09 May 2026
52,740 Shares in Tactile Systems Technology, Inc. $TCMD Bought by RFG Advisory LLC - MarketBeat
Fri, 08 May 2026
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 23 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 98.5 (%) |
| Shares Short | 1,660 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | 0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.76 |
| Profit Margin | 5.7 % |
| Operating Margin | 18.1 % |
| Return on Assets (ttm) | 6.4 % |
| Return on Equity (ttm) | 8.7 % |
| Qtrly Rev. Growth | 21 % |
| Gross Profit (p.s.) | 10.99 |
| Sales Per Share | 14.48 |
| EBITDA (p.s.) | 1.57 |
| Qtrly Earnings Growth | 17.6 % |
| Operating Cash Flow | 43 (M) |
| Levered Free Cash Flow | 35 (M) |
| PE Ratio | 28.09 |
| PEG Ratio | 17.7 |
| Price to Book value | 2.36 |
| Price to Sales | 1.59 |
| Price to Cash Flow | 12.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|